RxSight Q3 Revenue Falls 19% to $24.6M
RxSight reported a net loss of $16.2 million, compared with $9.8 million in Q3 2025. Cash, equivalents and short-term investments totaled $254.7 million, including $60 million received under its Alcon collaboration.
RxSight reported Q3 2026 revenue of $24.6M, down 19% year over year, and a net loss of $16.2M versus $9.8M in Q3 2025. Cash, equivalents and short-term investments totaled $254.7M, including $60M received under the Alcon collaboration.Material DetailsContext by AI AnalystThis is a quarterly update…